Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 8/20 | 0.61 |
| ▸ | MAOB | P27338 | 9/20 | 0.61 |
| ▸ | MAOA | P21397 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.56 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14601431 | 0.84 | HRH3 (0.59) | HRH3MAOBALDH1A1SMN1; SMN2MRGPRX4 | |
| SCHEMBL22139428 | 0.83 | HRH3 (0.62) | HRH3MRGPRX4 | |
| SCHEMBL13445251 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL14231550 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL28595922 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6822733 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15081033 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL6822864 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL12337677 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 | |
| SCHEMBL15905969 | 0.82 | HDAC8 (0.59) | ALDH1A1HTTSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-7163952-B2 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2007-01-16 | — | — | US | disclosed |
| US-20050065196-A1 | Azole compound and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-24 | — | — | US | disclosed |
| EP-1452530-A1 | AZOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065196-A1 | Azole compound and medicinal use thereof | PTPN7, PTPN1, PTPN5 | HRH3 840/4885MAOB 1036/4885MAOA 2356/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.